JPJuthi Pal

Juthi Pal

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Juthi Pal has a total of 13 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Redox‐Responsive Core Cross‐Linked Micelle as Anticancer Drug Delivery Vehicle

    by Gargi Biswas, Juthi Pal, Bikash Chandra Jena, Mahitosh Mandal, Dibakar Dhara

    Self‐assembled micelles are popular as a nanoplatform for cancer therapeutics. However, they still suffer from several drawbacks, like lower drug loading capacity and premature drug release. In order to overcome these issues, we have presently developed new redox‐responsive cross‐linked micelles using lipoic acid‐containing polymers, poly(NVP)‐ b ‐poly(LABPA). The self‐assembly behavior of the polymers was monitored before and after cross‐linking in the presence of a catalytic amount of glutathione (GSH). The core cross‐linked (CCL) polymeric micelles were further subjected to high GSH concentrations found in cancer cells, and the corresponding de‐cross‐linking of the core, followed by an analogous size change, was investigated using dynamic light scattering (DLS) and AFM measurements. In comparison to precursor polymers, the higher drug (doxorubicin; DOX) loading capacity (DLC) of 24.5% of the CCL micelles and GSH‐triggered rapid drug release suggested their importance as a potent drug delivery system for cancer therapy. Very often, a successful cancer treatment is inhibited by the drug resistance of the cancer cells. In this present work, the in vitro cytotoxicity study was performed using drug‐sensitive and drug‐resistant MDA‐MB‐231 cells, where a lower IC 50 value of the drug‐loaded CCL micelles was obtained in comparison to free DOX toward both drug‐sensitive and resistant cells, justifying their potential utility in cancer therapeutics. Briefly, our lipoic acid‐containing redox‐responsive polymers, poly(NVP)‐ b ‐poly(LABPA), show significantly enhanced drug loading capacity (24.5%), wonderful extracellular stability with rapid GSH‐triggered drug release in the intracellular redox environment, and importantly, the DOX‐loaded CCL micelles show significantly lower IC 50 values for both the parental and resistant cancer cells than free DOX, calling attention to their efficiency over other existing drug delivery vehicles.

  • Raspberry-like gold nano-conjugates of block copolymer prodrug based bicontinuous nanoparticles for cancer theranostics

    by Juthi Pal, Afruja Khan, Pousali Samanta, Manisha Khamrai, Amirul Islam Mallick, Dibakar Dhara


  • Bicontinuous Nanoparticles from Spontaneous Self-Assembly of Block Copolymer Prodrug in Aqueous Medium for Potential Cancer Therapy

    by Juthi Pal, Pousali Samanta, Afruja Khan, Rishabh Maity, Amirul Islam Mallick, Dibakar Dhara

    Despite having several advantages, bicontinuously structured polymeric nanoparticles (BSPNPs) are far less explored in the field of controlled drug delivery owing to the requirement of complex precursor copolymers and the associated multistep synthetic procedures. In this work, we report the synthesis of a redox-sensitive diblock copolymer (P1), which was subsequently utilized to prepare doxorubicin (DOX) containing a pH-labile prodrug (P2). P1 and P2 spontaneously self-assembled in aqueous media above their critical aggregation concentration, forming micellar nanoparticles with rare bicontinuous morphology that promotes loading of both hydrophobic and hydrophilic cargoes in different compartments. To the best of our knowledge, the formation of BSPNPs through direct self-assembly in aqueous media has not yet been reported. In vitro cellular studies asserted the higher safety profile of the nanoparticles against noncancerous cells (HEK293T) than free DOX, whereas they displayed higher drug-induced cytotoxicity against cancer cells (MCF-7) in comparison to free DOX, establishing them as promising cancer drug delivery systems.


  • Self-Indicating Polymer Prodrug Nanoparticles for pH-Responsive Drug Delivery in Cancer Cells and Real-Time Monitoring of Drug Release

    by Shibayan Kayal, Prithwish Kola, Juthi Pal, Mahitosh Mandal, Dibakar Dhara

    Amphiphilic self-indicating and responsive polymer-based prodrugs have generated much interest as potential stimuli-responsive intelligent drug delivery systems (DDS) due to their ability to selectively deliver drugs to the cancer cells and to monitor real-time cellular uptake of the drug by imaging technique(s). In this direction, we have synthesized a new pH-responsive N-vinyl-2-pyrrolidone and coumarin-based fluorescent self-indicating polymeric prodrug (SIPD), poly(NVP)-b-poly(FPA.DOX-r-FPA-r-CA). This block copolymer prodrug self-assembled into stable micellar nanoparticles under physiological conditions that reduced undesirable drug leakage to normal cells but resulted in the release of the anticancer drug doxorubicin (DOX) in cancer cells because of acidic pH-induced cleavage of imine bonds between DOX and the copolymer. While the polymer was found to be highly biocompatible with both normal (HEK-293) cells and cancer (MCF-7) cells even at high concentrations by MTT assay, the polymer prodrug nanoparticles showed toxicity even higher than that of free DOX in cancer cells. Phase contrast microscopy also depicted the cytotoxic effects of the nanoparticles on cancer cells. The coumarin units present in the polymer served as a fluorescence resonance energy transfer (FRET) pair with the covalently attached DOX molecules, which was established by steady-state and time-resolved fluorescence spectroscopy. Furthermore, confocal microscopy results confirmed the FRET phenomenon, as the fluorescence intensity of coumarin in the micellar nanoparticles remained quenched initially in MCF-7 cells but recovered with time as the DOX molecules were released and gradually shifted toward the targeted nucleus. All of these studies implied that the synthesized prodrug nanoparticles may provide another viable option for delivering chemotherapeutic drugs into cancer cells with a capability of real-time monitoring of drug release.


  • Polymer Nanoparticles for Preferential Delivery of Drugs Only by Exploiting the Slightly Elevated Temperature of Cancer Cells and Real-Time Monitoring of Drug Release

    by Juthi Pal, Prithwish Kola, Pousali Samanta, Mahitosh Mandal, Dibakar Dhara

    Rapid proliferation and a faster rate of glycolysis in cancer cells often result in an elevated local temperature (40-43 °C) at the tumor site. Nanoparticles prepared from polymers with two lower critical solution temperatures (LCSTs) can be utilized to take advantage of this subtle temperature elevation to deliver anticancer drugs preferably to the cancer cells, thereby enhancing the overall therapeutic efficacy and reducing side effects. In this direction, we synthesized N-vinyl-2-pyrrolidone (NVP) and substituted NVP (sub-NVP: C2-NVP, C4-NVP)-based polymers with precisely controlled LCSTs by varying the ratio of NVP and sub-NVP. The first LCST (LCST1) was kept below 37 °C to promote self-assembly, drug loading, and structural stability in physiological conditions and the second LCST (LCST2) was in the range of 40-43 °C to ensure mild hyperthermia-induced drug release. Additionally, covalent attachment of tetraphenylethylene (TPE, AIEgen) resulted in aggregation-induced emission in thermoresponsive micellar nanoparticles in which TPE acted as a Förster Resonance Energy Transfer (FRET) pair with the loaded anticancer drug doxorubicin (DOX). Tracking of FRET-induced fluorescence recovery of TPE molecules was utilized to confirm the real-time thermoresponsive release of DOX from nanoparticles and eventual localization of TPE in the cytoplasm and DOX in the nucleus. In vitro cellular studies such as cytotoxicity, cellular uptake, and thermoresponsive drug release showed that the DOX-loaded polymeric nanoparticles were nontoxic to normal cells (HEK-293) but significantly more effective in cancer cells (MCF-7) at 40 °C. To our knowledge, this is the first report of preferential delivery of anticancer drugs only by exploiting the slightly elevated temperature of cancer cells.